AR044579A1 - Antagonistas de nmda/ nr2b nonaril - heterociclicos n- sustituidos - Google Patents
Antagonistas de nmda/ nr2b nonaril - heterociclicos n- sustituidosInfo
- Publication number
- AR044579A1 AR044579A1 ARP040101878A ARP040101878A AR044579A1 AR 044579 A1 AR044579 A1 AR 044579A1 AR P040101878 A ARP040101878 A AR P040101878A AR P040101878 A ARP040101878 A AR P040101878A AR 044579 A1 AR044579 A1 AR 044579A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- alkyl
- nmda
- substituted
- nonaril
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
Abstract
Sales farmacéuticamente aceptables de los mismos, son eficaces como antagonistas de NMDA NR2B útiles para tratar afecciones tales como, por ejemplo, enfermedad de Parkinson, enfermedad de Alzheimer, migraña, epilepsia y dolor. Reivindicación 1: Un compuesto que tiene la fórmula (1), o las sales farmacéuticas de los mismos, en la que: HetAr es un anillo heteroaromático de 5 ó 6 eslabones que contiene 1 ó 2 átomos de nitrógeno en el anillo, tiazolilo, o tiadiazolilo; HetAr está opcionalmente sustituido con 1 o 2 sustituyentes, cada sustituyente independientemente es alquil c1-4, flúor, cloro, bromo, o yodo; A es un enlace o alquil-C1-2; y B es aril(CH2)0-3-O-C(O)-, indanil(CH2)0-3-O-C(O)-, aril(CH2)1-3-C(O)-, aril-ciclopropil-C(O)-, aril(CH2)1-3-NH-C(O)-, en el que cualquier arilo está opcionalmente sustituido con 1-5 sustituyentes, cada sustituyentes independientemente es alquilo C-14, fluoro, o cloro. R1 y R2 son independientemente, H, alquilo C1-4, fluoro, bromo o yodo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47593803P | 2003-06-04 | 2003-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044579A1 true AR044579A1 (es) | 2005-09-21 |
Family
ID=33511734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101878A AR044579A1 (es) | 2003-06-04 | 2004-05-31 | Antagonistas de nmda/ nr2b nonaril - heterociclicos n- sustituidos |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1648882B1 (es) |
| JP (1) | JP3927228B2 (es) |
| KR (1) | KR20060017839A (es) |
| CN (1) | CN1798744A (es) |
| AR (1) | AR044579A1 (es) |
| AT (1) | ATE403651T1 (es) |
| AU (1) | AU2004245522B2 (es) |
| BR (1) | BRPI0410837A (es) |
| CA (1) | CA2527093C (es) |
| CL (1) | CL2004001365A1 (es) |
| CO (1) | CO5700762A2 (es) |
| DE (1) | DE602004015610D1 (es) |
| DK (1) | DK1648882T3 (es) |
| EC (1) | ECSP056192A (es) |
| ES (1) | ES2309540T3 (es) |
| HR (1) | HRP20080490T3 (es) |
| IS (1) | IS8117A (es) |
| MA (1) | MA27781A1 (es) |
| MX (1) | MXPA05013151A (es) |
| MY (1) | MY138547A (es) |
| NO (1) | NO20060020L (es) |
| PE (1) | PE20050245A1 (es) |
| PL (1) | PL1648882T3 (es) |
| PT (1) | PT1648882E (es) |
| RU (1) | RU2339630C2 (es) |
| SI (1) | SI1648882T1 (es) |
| TW (1) | TW200510378A (es) |
| UA (1) | UA81319C2 (es) |
| WO (1) | WO2004108705A1 (es) |
| ZA (1) | ZA200509000B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009535364A (ja) * | 2006-05-03 | 2009-10-01 | シーエヌエスバイオ ピーティーワイ リミテッド | 炎症性疼痛の治療のための方法および組成物 |
| ES2400710T3 (es) * | 2007-04-23 | 2013-04-11 | Janssen Pharmaceutica, N.V. | Tia(dia)zoles como antagonistas del receptor de dopamina 2 de disociación rápida |
| EP2175886A1 (en) * | 2007-06-28 | 2010-04-21 | CNSBio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
| CN102762554A (zh) | 2010-02-16 | 2012-10-31 | 辉瑞大药厂 | 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 |
| AU2013251079B2 (en) | 2012-04-20 | 2017-03-23 | Ucb Pharma S.A. | Methods for treating Parkinson's disease |
| CN103936663B (zh) * | 2013-01-23 | 2016-12-28 | 艾琪康医药科技（上海）有限公司 | 一种1-r1-3,3-二氟(或3-氟)-4-r2-4-氨甲基哌啶及其衍生物的制备方法 |
| US9187506B2 (en) | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| US9221796B2 (en) | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| EP3152213B1 (en) | 2014-06-04 | 2018-10-31 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
| MX2017002775A (es) | 2014-09-15 | 2017-08-10 | Rugen Holdings (Cayman) Ltd | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. |
| US20180271869A1 (en) * | 2014-09-22 | 2018-09-27 | Jie Liu | Treatment of anxiety disorders and autism spectrum disorders |
| EP3237399B1 (en) * | 2014-12-23 | 2022-11-30 | Avalo Therapeutics, Inc. | Compounds, compositions and methods |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| CN107849010B (zh) | 2015-06-01 | 2021-11-09 | 卢郡控股(开曼)有限公司 | 作为nr2b nmda受体拮抗剂的3,3‐二氟哌啶氨基甲酸酯杂环化合物 |
| ES2822830T3 (es) | 2015-10-14 | 2021-05-05 | Bristol Myers Squibb Co | Antagonistas selectivos de NR2B |
| WO2017066366A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| TWI732031B (zh) | 2016-08-31 | 2021-07-01 | 日商衛材R&D企管股份有限公司 | 吡唑并[1, 5-a]嘧啶化合物 |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60210944T3 (de) * | 2001-02-23 | 2015-07-23 | Merck Sharp & Dohme Corp. | N-substituierte nichtaryl-heterocyclische nmda/nr2b antagonisten |
-
2004
- 2004-05-28 EP EP04753896A patent/EP1648882B1/en not_active Expired - Lifetime
- 2004-05-28 SI SI200430845T patent/SI1648882T1/sl unknown
- 2004-05-28 UA UAA200511411A patent/UA81319C2/uk unknown
- 2004-05-28 DK DK04753896T patent/DK1648882T3/da active
- 2004-05-28 PT PT04753896T patent/PT1648882E/pt unknown
- 2004-05-28 ES ES04753896T patent/ES2309540T3/es not_active Expired - Lifetime
- 2004-05-28 CN CNA2004800153228A patent/CN1798744A/zh active Pending
- 2004-05-28 HR HR20080490T patent/HRP20080490T3/xx unknown
- 2004-05-28 CA CA002527093A patent/CA2527093C/en not_active Expired - Lifetime
- 2004-05-28 AU AU2004245522A patent/AU2004245522B2/en not_active Expired
- 2004-05-28 DE DE602004015610T patent/DE602004015610D1/de not_active Expired - Lifetime
- 2004-05-28 AT AT04753896T patent/ATE403651T1/de not_active IP Right Cessation
- 2004-05-28 BR BRPI0410837-0A patent/BRPI0410837A/pt not_active IP Right Cessation
- 2004-05-28 JP JP2006515051A patent/JP3927228B2/ja not_active Expired - Lifetime
- 2004-05-28 PL PL04753896T patent/PL1648882T3/pl unknown
- 2004-05-28 RU RU2005137704/04A patent/RU2339630C2/ru not_active IP Right Cessation
- 2004-05-28 WO PCT/US2004/017175 patent/WO2004108705A1/en not_active Ceased
- 2004-05-28 KR KR1020057023218A patent/KR20060017839A/ko not_active Ceased
- 2004-05-28 MX MXPA05013151A patent/MXPA05013151A/es active IP Right Grant
- 2004-05-31 MY MYPI20042091A patent/MY138547A/en unknown
- 2004-05-31 AR ARP040101878A patent/AR044579A1/es unknown
- 2004-06-01 PE PE2004000552A patent/PE20050245A1/es not_active Application Discontinuation
- 2004-06-03 TW TW093115972A patent/TW200510378A/zh unknown
- 2004-06-03 CL CL200401365A patent/CL2004001365A1/es unknown
-
2005
- 2005-11-07 ZA ZA200509000A patent/ZA200509000B/en unknown
- 2005-11-07 IS IS8117A patent/IS8117A/is unknown
- 2005-11-28 MA MA28626A patent/MA27781A1/fr unknown
- 2005-11-29 EC EC2005006192A patent/ECSP056192A/es unknown
- 2005-11-30 CO CO05121658A patent/CO5700762A2/es not_active Application Discontinuation
-
2006
- 2006-01-03 NO NO20060020A patent/NO20060020L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044579A1 (es) | Antagonistas de nmda/ nr2b nonaril - heterociclicos n- sustituidos | |
| AR038136A1 (es) | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento | |
| CO5570667A2 (es) | Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades | |
| AR038047A1 (es) | Agentes terapeuticos | |
| PA8431301A1 (es) | Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion | |
| PE20040832A1 (es) | Derivados de indolil pirazinona | |
| UY26276A1 (es) | 1,2,4,5- tetrahidro-benzo (d) azepinas ley 17164 | |
| ES2623982T3 (es) | Compuestos heterocíclicos de unión a receptor de quimiocina con eficacia potenciada | |
| CO5580820A2 (es) | Derivados novedosos de acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| UY28135A1 (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
| ECSP055684A (es) | Antagonistas del receptor opiode | |
| CA2497868A1 (en) | Heterocyclic compounds | |
| UY27918A1 (es) | Derivados de benzodioxol | |
| CY1110997T1 (el) | Παραγωγο 2-αμινοδικυκλο [3.1.0] εξαν-2,6-δικαρβοξυλικου εστερα | |
| UY28101A1 (es) | Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer | |
| AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende | |
| CU23413B7 (es) | Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos | |
| PA8518701A1 (es) | Derivados de tiofeno utiles como agentes anticancerosos | |
| ECSP045258A (es) | Hidroxietilaminas sustituidas | |
| HN2003000272A (es) | Formulaciones que comprenden un compuesto de indolinona | |
| SV1999000039A (es) | Composicion farmaceutica ref. e3963-zi | |
| GT200000197A (es) | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida. | |
| AR033426A1 (es) | Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento | |
| MX2024012967A (es) | Derivados de piridina para el tratamiento de los trastornos psiquiatricos | |
| AR041898A1 (es) | Derivados de 4(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |